NAMD Comments on Final Outpatient Drug Rule

NAMD submitted comments to CMS on the final Medicaid covered outpatient drug rule. In the comments, NAMD calls attention to implementation timeline challenges posed by the rule and provides a suggested approach for handling line extension drugs.

Read full letter.


Comments are closed.